Treatment of latent tuberculosis infection

Systematic Review: T-Cell–based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update

(2013) Madhukar Pai et al.   ANNALS OF INTERNAL MEDICINE

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection

(2013) Dick Menzies et al.   ANNALS OF INTERNAL MEDICINE

Latent Tuberculosis Infection in the United States

(2011) C. Robert Horsburgh et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Regimens to Prevent Tuberculosis in Adults with HIV Infection

(2011) Neil A. Martinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

(2011) Timothy R. Sterling et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

(2010) A. Aspler et al.   THORAX

Latent TB Infection Treatment Acceptance and Completion in the United States and Canada

(2009) C. Robert Horsburgh et al.   CHEST

Detection and Prediction of Active Tuberculosis Disease by a Whole‐Blood Interferon‐γ Release Assay in HIV‐1–Infected Individuals

(2009) Maximilian C. Aichelburg et al.   CLINICAL INFECTIOUS DISEASES

Adherence to treatment of latent tuberculosis infection in a clinical population in New York City

(2009) Jiehui Li et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

(2009) L. J. Abu-Raddad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prevalence of Tuberculosis Infection in the United States Population

(2007) Diane E. Bennett et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE